OpenEvidence, headquartered in United States, remains privately held in the healthcare technology / ai medical search space. The latest valuation stands at $12B. The stock is not listed on any public market.
4 valuations. The latest, $12B post-money, was set by the Series D in Jan 2026.
Thrive CapitalLEAD
DST GlobalLEAD
Google VenturesLEAD
GVLEAD
Kleiner PerkinsLEADSSequoia CapitalLEAD
Nvidia
Blackstone
Craft Ventures
Mayo Clinic
Coatue
ConvictionThrive CapitalDST GlobalGoogle VenturesGVOpenEvidence operates an AI-powered medical search platform that gives clinicians point-of-care answers drawn from peer-reviewed literature, licensing content from journals such as The New England Journal of Medicine, JAMA, Nature, and Cochrane Systematic Reviews. Founded in 2022, the company describes itself as the most widely used medical AI among verified U.S. clinicians.
More than 100 million Americans will be treated in 2026 by a clinician using OpenEvidence, and the platform has supported over 200 million AI-powered clinical consultations to date.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds OpenEvidence.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. OpenEvidence availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — OpenEvidence included.
The routes section explains what is realistically available for a company at this stage.
No. OpenEvidence is a private company; its shares do not trade on a public exchange.
The last valuation is $12B.
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
